Wall Street Journal Statement Regarding Theranos CEO Interview at WSJD Live See video below
Full Interview: Theranos CEO Elizabeth Holmes
At the WSJDLive 2015 conference, Theranos founder and CEO Elizabeth Holmes discusses her company’s proprietary technologies, the FDA’s inspection of its facilities, and the assertion that her company was too quick to market its products.
NEW YORK (October 21, 2015) — The Wall Street Journal has released the following statement regarding today’s interview of Theranos CEO Elizabeth Holmes at WSJD Live (#wsjdlive) in Laguna Beach, Calif.:
Below is our 13F roundup for some high profile hedge funds for the three months to the end of March 2021 (Q1). Q1 2021 hedge fund letters, conferences and more The statements only include equity positions as 13Fs do not include cash and debt holdings. They also only include US equity holdings. Funds may hold Read More
“We’d like to thank Theranos CEO Elizabeth Holmes for agreeing to an interview today at our WSJDLive 2015 conference, and for the opportunity she gave all of our readers and viewers to hear from her. We always seek full input from the subjects of stories, as we did repeatedly throughout our reporting on Theranos.
Nothing said at the conference by Ms. Holmes refutes the accuracy of the reporting done by John Carreyrou or of the articles, which were subject to the Journal’s rigorous and careful editing process. Contrary to Ms. Holmes’s claims, the Journal shared all facts and anecdotes published in the articles with Theranos before publication, in accordance with our longstanding editorial practice and principles. The company was given plenty of opportunity to respond. Ms. Holmes declined interview requests from the Journal for more than five months, but the general counsel and outside counsel of Theranos provided significant input, which was fairly reflected in the articles.
We note that Ms. Holmes sought to challenge the reliability of our sources, but it remains the fact that she doesn’t know from whom the information for our articles was gathered. We assure her and our readers that our sources were well positioned to know the information they provided about Theranos, and they were vetted before publication.
The Journal reiterates that our articles about Theranos were thoroughly reported, fair and wholly accurate.”